Zoely: combined oral contraceptive containing new progestogen

Zoely is the first combined oral contraceptive to use nomegestrol as its progesterone component.

Zoely is taken continuously, in 28-day cycles consisting of 24 active therapy days followed by 4 placebo days.
Zoely is taken continuously, in 28-day cycles consisting of 24 active therapy days followed by 4 placebo days.


Zoely is a combined oral contraceptive containing nomegestrol acetate, a highly selective progestogen, and estradiol, a natural oestrogen. Nomegestrol acetate has no oestrogenic, androgenic, glucocorticoid or mineralocorticoid activity.1


The safety and efficacy of the estradiol/nomegestrol combination were assessed in two open-label phase III trials, one conducted in Europe and one performed in the US. Participants were randomised to receive 1.5mg estradiol/2.5mg nomegestrol acetate or 30 microgram ethinylestradiol/3mg drospirenone (Yasmin).1


In women aged ≤35 years in the European trial (n=1,757), Pearl Indices (pregnancies per 100 woman-years) were:

  • 0.38 (95% CI 0.10–0.97) for estradiol/nomegestrol, compared with
  • 0.81 for ethinylestradiol/drospirenone (95% CI 0.17–2.35).2

In the US study, Pearl Indices in the same age group (n=1,838) were 1.27 (95% CI 0.66–2.22) and 1.89 (95% CI 0.69–4.11), respectively.3

Safety profile

The estradiol/nomegestrol combination was well tolerated in both studies, with acne and irregular withdrawal bleeding the most common adverse effects.1–3


  1. Zoely Summary of Product Characteristics, August 2012.
  2. Mansour D et al. Eur J Contracept Reprod Health Care 2011; 16; 430–43.
  3. Westhoff C et al. Obstet Gynecol 2012; 119: 989–999.

View Zoely drug record
Further information: Merck Sharp & Dohme Ltd

Follow MIMS on Twitter

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases